Published in Int J Radiat Oncol Biol Phys on May 01, 2003
Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer (2011) 1.63
Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. Int J Radiat Oncol Biol Phys (2008) 1.56
Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys (2011) 1.32
Heavy charged particle radiobiology: using enhanced biological effectiveness and improved beam focusing to advance cancer therapy. Mutat Res (2011) 1.05
Particle therapy for non-small cell lung tumors: where do we stand? A systematic review of the literature. Front Oncol (2014) 0.94
Review of clinical experience with ion beam radiotherapy. Br J Radiol (2011) 0.91
Clinical evidence of particle beam therapy (proton). Int J Clin Oncol (2012) 0.85
High-dose concurrent chemo-proton therapy for Stage III NSCLC: preliminary results of a Phase II study. J Radiat Res (2014) 0.82
Comparisons of dose-volume histograms for proton-beam versus 3-D conformal x-ray therapy in patients with stage I non-small cell lung cancer. Strahlenther Onkol (2009) 0.80
Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review. Oncologist (2010) 0.79
Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiother Oncol (2017) 0.75
PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med (2004) 4.64
JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem (2005) 2.76
Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin j(2). Mol Cell Biol (2004) 2.25
Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells (2005) 2.18
A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2009) 2.06
Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res (2009) 2.04
Role of 15-deoxy delta(12,14) prostaglandin J2 and Nrf2 pathways in protection against acute lung injury. Am J Respir Crit Care Med (2005) 1.94
Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension (2002) 1.83
Polymorphisms of IL4, IL13, and ADRB2 genes in COPD. Chest (2004) 1.79
Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J Immunol (2005) 1.79
Retinoic acid inhibits elastase-induced injury in human lung epithelial cell lines. Am J Respir Cell Mol Biol (2003) 1.67
Limited thymectomy for stage I or II thymomas. Lung Cancer (2009) 1.64
Gemcitabine-induced pulmonary toxicity in a patient with pancreatic cancer. JOP (2010) 1.59
Insulin-induced GLUT4 translocation involves protein kinase C-lambda-mediated functional coupling between Rab4 and the motor protein kinesin. Mol Cell Biol (2003) 1.56
Calculation of rotational setup error using the real-time tracking radiation therapy (RTRT) system and its application to the treatment of spinal schwannoma. Int J Radiat Oncol Biol Phys (2002) 1.52
High incidence of aspiration pneumonia in community- and hospital-acquired pneumonia in hospitalized patients: a multicenter, prospective study in Japan. J Am Geriatr Soc (2008) 1.49
Clinical Results of Carbon Ion Radiotherapy at NIRS. J Radiat Res (2007) 1.49
Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Science (NIRS). J Radiat Res (2010) 1.46
Adenoviral E1A suppresses secretory leukoprotease inhibitor and elafin secretion in human alveolar epithelial cells and bronchial epithelial cells. Respiration (2005) 1.46
Identification of polymorphisms in the promoter region of the human NRF2 gene. Biochem Biophys Res Commun (2004) 1.40
Pneumonitis due to an herbal medicine, Otsu-ji-to. Eur J Intern Med (2010) 1.38
Effects of rhinovirus infection on the adherence of Streptococcus pneumoniae to cultured human airway epithelial cells. J Infect Dis (2003) 1.35
Correlation between the respiratory waveform measured using a respiratory sensor and 3D tumor motion in gated radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.33
Association of susceptibility to the development of lung adenocarcinoma with the heme oxygenase-1 gene promoter polymorphism. Hum Genet (2005) 1.32
Spectrum of germ cell tumors: from head to toe. Radiographics (2004) 1.29
Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med (2009) 1.26
Interstitial pneumonia developed in a worker dealing with particles containing indium-tin oxide. J Occup Health (2003) 1.25
Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull. Int J Radiat Oncol Biol Phys (2003) 1.24
Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res (2005) 1.24
G protein-coupled receptor kinase 2 mediates endothelin-1-induced insulin resistance via the inhibition of both Galphaq/11 and insulin receptor substrate-1 pathways in 3T3-L1 adipocytes. Mol Endocrinol (2005) 1.23
Suppression of eosinophilic airway inflammation by treatment with alpha-galactosylceramide. Eur J Immunol (2005) 1.22
Serum levels of CA19-9 in patients with nonmalignant respiratory diseases. J Clin Lab Anal (2007) 1.22
Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clin Exp Nephrol (2013) 1.20
Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features. Lung Cancer (2012) 1.17
Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys (2007) 1.15
Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol (2012) 1.14
Specific organ metastases and survival in small cell lung cancer. Oncol Lett (2012) 1.13
Langerhans cell sarcoma of the cervical lymph node: a case report and literature review. Auris Nasus Larynx (2010) 1.12
Radiotherapy for hepatocellular carcinoma: an overview. Ann Surg Oncol (2008) 1.10
Real-time monitoring of a digestive tract marker to reduce adverse effects of moving organs at risk (OAR) in radiotherapy for thoracic and abdominal tumors. Int J Radiat Oncol Biol Phys (2005) 1.10
A patient with pulmonary lymphangitic carcinomatosis successfully treated with TS-1 and cisplatin. Intern Med (2007) 1.10
Cdc42 is a Rho GTPase family member that can mediate insulin signaling to glucose transport in 3T3-L1 adipocytes. J Biol Chem (2003) 1.10
GRK2 is an endogenous protein inhibitor of the insulin signaling pathway for glucose transport stimulation. EMBO J (2004) 1.10
Prevalence of COPD. Respirology (2014) 1.08
Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol (2009) 1.06
Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer (2005) 1.06
Clinical results of proton beam therapy for cancer of the esophagus. Int J Radiat Oncol Biol Phys (2005) 1.05
Repeated proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.05
Clinical results of proton beam therapy for skull base chordoma. Int J Radiat Oncol Biol Phys (2004) 1.05
Proton beam therapy interference with implanted cardiac pacemakers. Int J Radiat Oncol Biol Phys (2008) 1.04
Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys (2010) 1.04
Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2009) 1.04
Transcription factors T-bet and GATA-3 regulate development of airway remodeling. Am J Respir Crit Care Med (2006) 1.03
Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer (2009) 1.03
Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the university of tsukuba. Int J Radiat Oncol Biol Phys (2010) 1.03
Antiproliferative property of sphingosine 1-phosphate in rat hepatocytes involves activation of Rho via Edg-5. Gastroenterology (2003) 1.02
Isoform-dependent cholesterol efflux from macrophages by apolipoprotein E is modulated by cell surface proteoglycans. Arterioscler Thromb Vasc Biol (2003) 1.01
Evaluation of liver function after proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2012) 1.01
Mechanisms of mucin production by rhinovirus infection in cultured human airway epithelial cells. Respir Physiol Neurobiol (2005) 1.01
Pathologic radioresponse of preoperatively irradiated invasive thymomas. J Thorac Oncol (2008) 1.01
A population-based study of gefitinib in patients with non-small cell lung cancer. Med Oncol (2008) 0.99
Proton beam therapy of Stage II and III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2010) 0.99